CapsoVision (NASDAQ:CV) executives used a fireside chat hosted by Roth Senior Research Analyst Kyle Bauser to outline the ...

Also on March 16, 2026, CapsoVision decided to halt pursuit of FDA clearance for its first-generation CapsoCam Colon following regulators’ questions on image processing and study design, redirecting ...

Fourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024. The primary growth ...

CapsoVision (NASDAQ:CV) executives highlighted continued commercial growth for its CapsoCam Plus small-bowel capsule ...

(the “Company”) (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the closing of a $14 million private ...

A soft sensor for colonoscopes has achieved 92 % accuracy in bleeding detection, improving safety during gastrointestinal ...

On March 26th, 2026, CapsoVision, a pioneering healthcare company, hosted its fourth-quarter and full-year 2025 earnings ...

Monitoring symptoms, recognizing unusual changes taking place in the body and following screening guidelines are among the ...

Q4 2025 earnings call: 15% revenue growth, $3.9M sales, CapsoCam Colon Gen 2/AI 510(k) timing, trials & funding—read now.

BATON ROUGE, La. (WAFB) - Colon cancer is the second leading cause of cancer-related deaths worldwide, according to the World Health Organization. March is Colon Cancer Awareness Month. While ...

According to the American Cancer Society, colorectal cancer is one of the leading causes of cancer in men and women.

Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 - SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a co ...